: Redefining Legal Work: How Legalfly uses AI to power the future of law with Ruben Miessen

entrepreneurship
co:lab podcast logo

In this final episode of the first season of the 𝗰𝗼:𝗹𝗮𝗯 𝗽𝗼𝗱𝗰𝗮𝘀𝘁, Glenn L’hoëst welcomes Ruben Miessen, CEO and co-founder of Legalfly, a rapidly growing legal AI company transforming the way legal work gets done.

blue dots of co:lab

Legalfly was born out of Ruben’s experience at Tinder, where he witnessed first-hand how legal teams were seen as bottlenecks due to repetitive and time-consuming tasks. Together with his co-founders, he set out to build an AI-native workspace that would automate everything from contract reviews to drafting and due diligence, freeing up legal teams to focus on higher-value, strategic work.

In just 18 months, Legalfly has grown to a team of 32, raised €17 million in funding, and now supports clients across 10 legal jurisdictions. Their approach combines cutting-edge AI with legal expertise, offering a highly autonomous, privacy-conscious platform that’s already reshaping how law firms and in-house legal departments operate.

In the conversation, Ruben shares what it takes to scale a legal tech company in a highly regulated environment, why AI won’t replace lawyers but will transform their roles, and how he balances the intense demands of startup life with family and focus. This is a must-listen for anyone working at the intersection of legal, AI, and entrepreneurship.

 

other podcasts

photo of Nico Huybrechts during co:lab podcast
Season 2 Episode 8
Scaling Datashift: Nico Huybrechts on Growth, Governance and AI 
In the final episode of this co:lab season, we sit down with Nico Huybrechts, founder and CEO of Datashift. Ten years ago, Datashift started at the kitchen table. Today, it is a multidisciplinary data & AI consultancy operating across borders. But this conversation goes beyond numbers.
podcast colab ep.7 - Leen Limbourg
Season 2 Episode 7
How life sciences innovation survives uncertainty with investor Leen Limbourg
In this episode of co:lab, we speak with Leen Limbourg, medical doctor, investor and experienced board member, about the realities of building and funding life sciences companies in today’s challenging environment.